Principal Financial Group Inc. Has $25.23 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Financial Group Inc. increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.2% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 258,495 shares of the medical equipment provider's stock after purchasing an additional 74,149 shares during the period. Principal Financial Group Inc. owned about 0.38% of Lantheus worth $25,229,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lantheus by 3.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after buying an additional 400 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Lantheus by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock worth $794,000 after acquiring an additional 215 shares during the period. GAMMA Investing LLC grew its stake in Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Lantheus by 12.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 10,294 shares of the medical equipment provider's stock valued at $921,000 after purchasing an additional 1,113 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 1,196.4% in the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Performance

LNTH traded down $2.52 on Friday, hitting $81.31. The company had a trading volume of 816,768 shares, compared to its average volume of 975,278. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The company's fifty day moving average price is $80.26 and its 200 day moving average price is $89.93. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of 23.10 and a beta of 0.12. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm's revenue was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 EPS. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on LNTH. Truist Financial dropped their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. B. Riley cut their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.